BioArctic's partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer's disease at CTAD conference

STOCKHOLM, Nov. 30, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ)...